Llobet D, Mojal S, Vallvé C, Carrasco M, Vilalta N, Mateo J, Moret C, Millón J, Soria J M, Souto J C
Hemostasis and Thrombosis, Institut de Recerca Sant Pau (IR Sant Pau), Sant Quintí 77-79, 08041, Barcelona, Spain.
Center for Biomedical Network Research of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
J Thromb Thrombolysis. 2025 Aug 14. doi: 10.1007/s11239-025-03165-4.
The von Willebrand factor/ADAMTS13 ratio and shortened PFA-100 values have been associated with the risk of venous thromboembolism (VT). Our objective was to confirm the association of the VWF/ADAMTS13 ratio with VT risk and to assess the correlation between this ratio and PFA-100 values. We determined ADAMTS13 and VWF plasma levels, as well as PFA-100 values in 800 individuals (400 with VT and 400 healthy controls) from the RETROVE project. Using binary logistic regression and multivariate analyses, we evaluated the relationship between the VWF/ADAMTS13 ratio and VT risk. Quartile cut-offs of this ratio were calculated in controls, after which we estimated odds ratios (ORs) with 95% CIs. The risk of VT increased progressively with increasing quartiles of the VWF/ADAMTS13 ratio, with an OR of 4.12 (95% CI, 2.47-6.88) for the highest vs lowest quartiles in an age-adjusted analysis. When we analyzed the ROC curve for the VWF/ADAMTS13 ratio, we found similar results: we obtained three ranges of this ratio, with an increasingly progressive risk (ORs from 2.59 to 6.54). Values of the VWF/ADAMTS13 ratio correlated negatively with PFA-100 (R = - 0.5 p < 0.001). These findings indicate that the VWF/ADAMTS13 ratio is an indicator of VT risk and that a high ratio correlates negatively with PFA-100 values.
血管性血友病因子/含血小板解聚蛋白和金属蛋白酶13(ADAMTS13)比值以及缩短的血小板功能分析仪-100(PFA-100)值与静脉血栓栓塞症(VT)风险相关。我们的目的是证实血管性血友病因子/ADAMTS13比值与VT风险的关联,并评估该比值与PFA-100值之间的相关性。我们测定了来自RETROVE项目的800名个体(400名VT患者和400名健康对照)的ADAMTS13和血管性血友病因子血浆水平以及PFA-100值。使用二元逻辑回归和多变量分析,我们评估了血管性血友病因子/ADAMTS13比值与VT风险之间的关系。在对照组中计算该比值的四分位数切点,之后我们估计了95%置信区间的比值比(OR)。VT风险随着血管性血友病因子/ADAMTS13比值四分位数的增加而逐渐增加,在年龄调整分析中,最高四分位数与最低四分位数相比,OR为4.12(95%置信区间,2.47 - 6.88)。当我们分析血管性血友病因子/ADAMTS13比值的ROC曲线时,我们得到了类似结果:我们获得了该比值的三个范围,风险逐渐增加(OR从2.59到6.54)。血管性血友病因子/ADAMTS13比值与PFA-100呈负相关(R = -0.5,p < 0.001)。这些发现表明血管性血友病因子/ADAMTS13比值是VT风险的一个指标,且高比值与PFA-100值呈负相关。